Author

G. N. Fuller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Mahajan· 1 shared A. Shetty· 1 shared C. J. Logothetis· 1 shared C. Kamiya-Matsuoka· 1 shared D. Piwnica-Worms· 1 shared F. F. Lang· 1 shared F. Santos-Pinheiro· 1 shared I. E. McCutcheon· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Mahajan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Measuring the metabolic evolution of glioblastoma throughout tumor development, regression, and recurrence with hyperpolarized magnetic resonance

T. C. Salzillo, V. Mawoneke, J. Weygand, A. Shetty, J. Gumin, N. M. Zacharias Millward, S. T. Gammon, D. Piwnica-Worms, G. N. Fuller, C. J. Logothetis, F. F. Lang, P. K. Bhattacharya

This study uses hyperpolarized MRI to track metabolic changes in glioblastoma across development, regression, and recurrence, showing its superior sensitivity compared to conventional MRI.

bioRxiv · Jun 10, 2021Biophysics

Pituitary Carcinoma: The University of Texas MD Anderson Cancer Center Experience.

F. Santos-Pinheiro, M. Penas-Prado, C. Kamiya-Matsuoka, S. G. Waguespack, A. Mahajan, P. D. Brown, K. B. Shah, G. N. Fuller, I. E. McCutcheon

This study reports on 17 pituitary carcinoma patients treated at MDACC, finding that TMZ-based therapy correlates with longer disease control and higher survival rates.

bioRxiv · Sep 10, 2018Cancer Biology